Minocycline Treatment for Cystoid Macular Edema (MINOCME)

Sun Yat-sen University

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Minocycline; Cystoid Macular Edema

Treatments: Drug: minocycline

Study type: Interventional

Funder types: Other

Identifiers

NCT05474950

MINOCME

Details and patient eligibility

About

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

Enrollment: 5 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant diagnosed with CME.
• Participant aged from 18-60 years old.
• Participant that signed the informed consent document and is able to complete the following visits.

Exclusion criteria

• Participant is allergy to minocycline or tetracyclines.
• Participant has no contraindications of minocycline or tetracyclines.
• Participant has an abnormal function of liver, heart, kidney and thyroid.
• Female that is pregnant, breast-feeding or planning to become pregnant.
• Participant that is currently using other medications.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

minocycline

Experimental group

Treatment:

Drug: minocycline